The Relative Strength (RS) Rating for BioNTech ADR headed into a higher percentile Friday, as it got a lift from 63 to 75.
IBD's proprietary RS Rating tracks market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the market's biggest winners tend to have an 80 or higher RS Rating as they begin their biggest price moves. See if BioNTech ADR can continue to rebound and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
BioNTech ADR is trying to complete a consolidation with a 131.49 entry. See if it can clear the breakout price in volume at least 40% above average.
Earnings grew 29% last quarter, up from 0% in the prior report. Revenue also increased, from -25% to 46%.
BioNTech ADR earns the No. 146 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
